Future oncology最新文献_第3页

Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects. 左乙曲坦和丙戊酸在胶质瘤中的作用：抗癫痫和潜在的抗肿瘤作用。

IF 3 4区医学

Future oncology Pub Date : 2025-02-01 Epub Date: 2025-01-09 DOI: 10.1080/14796694.2025.2450215

Bobak F Khalili, Tobias Walbert, Craig Horbinski, Karan Dixit, Kapil Gururangan, Helen Thio, Matthew C Tate, Roger Stupp, Rimas V Lukas, Jessica W Templer

{"title":"Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects.","authors":"Bobak F Khalili, Tobias Walbert, Craig Horbinski, Karan Dixit, Kapil Gururangan, Helen Thio, Matthew C Tate, Roger Stupp, Rimas V Lukas, Jessica W Templer","doi":"10.1080/14796694.2025.2450215","DOIUrl":"10.1080/14796694.2025.2450215","url":null,"abstract":"Seizures are a frequent complication in glioma. Incidence of brain tumor-related epilepsy (BTRE) in high-grade glioma (HGG) is an estimated > 25% and in low-grade glioma (LGG) is approximately 72%. Two first-line antiseizure medications (ASMs) for BTRE include levetiracetam (LEV) and valproic acid (VPA). Use of VPA has decreased because of a broader side effect profile, potential interaction with chemotherapeutic drugs, and availability of newer generation agents. In refractory BTRE, LEV and VPA may be prescribed together to enhance seizure control. VPA and LEV have gained attention for their purported antineoplastic effects and synergistic role with temozolomide. VPA is suggested to modulate anticancer activity in vitro through multiple mechanisms. In addition, retrospective studies indicate increased overall survival in patients with epileptogenic HGGs who are managed with LEV or VPA rather than other ASMs. However, these studies have numerous limitations. It is also reported that patients with glioma and a seizure history have a longer survival. This extended survival, if one exists, may be only observed in certain gliomas with corresponding patient characteristics. We provide a brief overview of the management of BTRE, VPA and LEV as anticonvulsants and antineoplastics, and the factors that may be associated with survival in epileptogenic glioma.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"483-491"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma. CASE （CemiplimAb-rwlc生存和流行病学）：一项晚期基底细胞癌的研究。

IF 3 4区医学

Future oncology Pub Date : 2025-02-01 Epub Date: 2025-01-11 DOI: 10.1080/14796694.2024.2448416

Soo J Park, David M Ellison, Ryan Weight, Jade Homsi, Guilherme Rabinowits, Emily S Ruiz, John Strasswimmer, Josh Simmons, Timothy Panella, Ruben Gw Quek, Jean-Francois Pouliot, Nikhil I Khushalani

{"title":"CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma.","authors":"Soo J Park, David M Ellison, Ryan Weight, Jade Homsi, Guilherme Rabinowits, Emily S Ruiz, John Strasswimmer, Josh Simmons, Timothy Panella, Ruben Gw Quek, Jean-Francois Pouliot, Nikhil I Khushalani","doi":"10.1080/14796694.2024.2448416","DOIUrl":"10.1080/14796694.2024.2448416","url":null,"abstract":"Patients diagnosed with metastatic basal cell carcinoma (BCC) have a poor prognosis. The current standard of care for adults with locally advanced or metastatic BCC who are not candidates for surgery or radiation therapy is treatment with hedgehog pathway inhibitors (HHIs). For patients who progress while on this therapy, further treatment options are limited. There is also a need for real-world clinical practice data on the clinical characteristics, management, disease progression, and survivorship of these patients. The ongoing CemiplimAb-rwlc Survivorship and Epidemiology (CASE) study is a phase IV, multicenter, prospective, noninterventional survivorship and epidemiology cohort study evaluating the effectiveness and safety of cemiplimab, a fully human immunoglobulin G4 monoclonal antibody that blocks the interaction between the programmed cell death-1 (PD-1) receptor and its ligands. This paper describes one cohort of the CASE study of patients with locally advanced or metastatic BCC who have failed or are intolerant of HHIs or for whom HHI therapy is not appropriate. Outcome measures of the study include response to treatment, quality of life, safety, treatment patterns, patient experience, and survival. This study could provide a more complete characterization of this patient population and fill knowledge gaps related to real-world treatment utilization and patient outcomes.Clinical Trial registration: NCT03836105.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"431-436"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142964488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain language summary of the ZUMA-7 study of axicabtagene ciloleucel versus standard of care for people with relapsed or refractory large B-cell lymphoma. axicabtagene ciloleucel与复发或难治性大b细胞淋巴瘤患者标准治疗的ZUMA-7研究的简明语言总结。

IF 3 4区医学

Future oncology Pub Date : 2025-02-01 Epub Date: 2025-01-12 DOI: 10.1080/14796694.2024.2435214

Frederick L Locke, Jason R Westin, Christina To

引用次数: 0

Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey. 医生的知识，使用和认识的遗传生物标志物检测管理的新诊断晚期卵巢癌患者：一项国际医师调查。

IF 3 4区医学

Future oncology Pub Date : 2025-02-01 Epub Date: 2025-01-15 DOI: 10.1080/14796694.2025.2449782

Susana Banerjee, Ramez N Eskander, Tom Bailey, Will Ambler, Stephanie Volpe, Ozan Özgören, Jacek P Grabowski, Giorgio Valabrega

{"title":"Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey.","authors":"Susana Banerjee, Ramez N Eskander, Tom Bailey, Will Ambler, Stephanie Volpe, Ozan Özgören, Jacek P Grabowski, Giorgio Valabrega","doi":"10.1080/14796694.2025.2449782","DOIUrl":"10.1080/14796694.2025.2449782","url":null,"abstract":"Aims: To explore physician-reported knowledge, use, and perceptions of genetic testing for advanced ovarian cancer management.Materials & methods: Gynecology/oncology specialists (n = 390) in the US, Europe, Canada, Japan, and Australia completed an online survey spanning March 2021 to April 2022.Results: Physician-reported breast cancer gene mutation (BRCAm) testing rates increased over the 2 years before the survey; most patients underwent testing in the preceding 6 months. Homologous recombination deficiency (HRD) genomic instability testing rates and physicians' confidence interpreting results remained relatively low. Genetic testing was driven by the associated treatment implications of the findings. Poor performance status, inadequate tissue, and patients' willingness to undergo testing were reported barriers to testing.Conclusions: Findings indicate that there is a need to improve both access to and information about HRD testing.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"437-445"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients. METTL4和METTL5作为肝细胞癌患者无复发生存的生物标志物

IF 3 4区医学

Future oncology Pub Date : 2025-02-01 Epub Date: 2024-12-20 DOI: 10.1080/14796694.2024.2442296

Jialing Zhao, Ruiqi Sun, Liang Zhi, Danjing Guo, Sunbin Ling, Xiangnan Liang, Jianhui Li, Changku Jia

{"title":"METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.","authors":"Jialing Zhao, Ruiqi Sun, Liang Zhi, Danjing Guo, Sunbin Ling, Xiangnan Liang, Jianhui Li, Changku Jia","doi":"10.1080/14796694.2024.2442296","DOIUrl":"10.1080/14796694.2024.2442296","url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, with high rates of postoperative recurrence. Identifying reliable biomarkers for predicting recurrence is critical for improving patient outcomes. This study investigates the predictive value of m6A methylation-related genes, METTL4 and METTL5, on HCC recurrence after surgery.Research design and methods: We analyzed METTL4 and METTL5 expression in HCC and adjacent non-cancerous tissues using the TCGA database and evaluated their levels in surgical samples from 67 hCC patients. A recurrence risk model was developed and validated in an external cohort of 65 patients.Results: METTL4 and METTL5 were significantly overexpressed in HCC tissues. High expression correlated with shorter recurrence-free survival (RFS). The model stratified patients into high, medium, and low-risk groups with 3-year RFS rates of 18.75%, 69.70%, and 93.75%, respectively.Conclusions: METTL4 and METTL5 expression levels are strong predictors of HCC recurrence. The risk model offers a novel approach for postoperative management of HCC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"331-340"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker? 肿瘤突变负担：为什么它仍然是一个有争议的不可知论免疫治疗生物标志物？

IF 3 4区医学

Future oncology Pub Date : 2025-02-01 Epub Date: 2024-12-23 DOI: 10.1080/14796694.2024.2444862

Antoine Mouawad, Marc Boutros, Antoine Chartouni, Fouad Attieh, Hampig Raphaël Kourie

引用次数: 0

A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4-20 ng/mL. PSA水平在4 ~ 20 ng/mL的患者，用凝血标志物预测前列腺癌的nomogram（图）。

IF 3 4区医学

Future oncology Pub Date : 2025-02-01 Epub Date: 2024-12-23 DOI: 10.1080/14796694.2024.2445499

Feifan Liu, Jianyu Wang, Yufeng Song, Fei Wu, Haihu Wu, Jiaju Lyu, Hao Ning

{"title":"A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4-20 ng/mL.","authors":"Feifan Liu, Jianyu Wang, Yufeng Song, Fei Wu, Haihu Wu, Jiaju Lyu, Hao Ning","doi":"10.1080/14796694.2024.2445499","DOIUrl":"10.1080/14796694.2024.2445499","url":null,"abstract":"Background: The global incidence of prostate cancer (PCa) is rising, necessitating improved diagnostic strategies. This study explores coagulation parameters' predictive value for clinically significant PCa (csPCa) and develops a nomogram.Research design and methods: This study retrospectively analyzed data from 702 patients who underwent prostate biopsy at Shandong Provincial Hospital (SDPH) and 142 patients at Shandong Cancer Hospital and Institute (SDCHI). SDPH patients were randomly assigned at a 7:3 ratio for internal validation, while SDCHI data served as external validation. LASSO and logistic regression identified the best predictive factors for csPCa, which were used to construct a model. The model's efficacy was tested using AUC, calibration curves, and decision curve analysis.Results: TPSA, age, D-dimer, prostate volume (PV), and digital rectal examination (DRE) were identified as independent risk factors for csPCa. A predictive model was constructed using a nomogram. The AUC for the training set was 0.841, for internal validation 0.809, and for external validation 0.814. Calibration and decision curves confirmed the model's clinical utility.Conclusions: The nomogram incorporating D-dimer, TPSA, age, PV, and DRE provides a highly accurate tool for assessing csPCa risk in individuals with PSA levels of 4-20 ng/mL, supporting personalized diagnostics and clinical decision-making.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"463-471"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study.

IF 3 4区医学

Future oncology Pub Date : 2025-01-31 DOI: 10.1080/14796694.2024.2415192

Thomas Powles, Begoña P Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman-Censits, Gopa Iyer, Christof Vulsteke, Se Hoon Park, Sang Joon Shin, Daniel Castellano, Giuseppe Fornarini, Jian-Ri Li, Mahmut Gümüş, Nataliya Mar, Yohann Loriot, Aude Fléchon, Ignacio Duran, Alexandra Drakaki, Sujata Narayanan, Xuesong Yu, Seema Gorla, Blanca Homet Moreno, Michiel S Van der Heijden

引用次数: 0

Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study.

IF 3 4区医学

Future oncology Pub Date : 2025-01-30 DOI: 10.1080/14796694.2025.2449754

Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, Andre P Fay, Ugo De Giorgi, Jae Young Joung, Peter C C Fong, Eric Voog, Robert J Jones, Neal D Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G Healy, Nicola Di Santo, A Douglas Laird, Fabian Zohren, Neeraj Agarwal

引用次数: 0

Evaluating patients on CDK-4/6 inhibitor treatment for differences in treatment according to demographic variables.

IF 3 4区医学

Future oncology Pub Date : 2025-01-26 DOI: 10.1080/14796694.2025.2455929

Sneha Rajendran, Marina Petruzzi, Dianxu Ren, Catherine Bender, Adam Brufsky, Margaret Q Rosenzweig

{"title":"Evaluating patients on CDK-4/6 inhibitor treatment for differences in treatment according to demographic variables.","authors":"Sneha Rajendran, Marina Petruzzi, Dianxu Ren, Catherine Bender, Adam Brufsky, Margaret Q Rosenzweig","doi":"10.1080/14796694.2025.2455929","DOIUrl":"https://doi.org/10.1080/14796694.2025.2455929","url":null,"abstract":"Background: The accessibility and outcomes of cyclin-dependent kinase 4 and 6 inhibitors (CDKi) in metastatic breast cancer (MBC) according to demographic factors are unknown.Research design and methods: Retrospective review of patients with ER+ MBC prescribed first-line CDKi therapy from January 2015 through December 2022. Abstraction included time from CDKi prescription to drug initiation (TTI), time from CDKi initiation to progression (TTP), time from CDKi initiation to death or 6/30/2022, and variables (age, race, partner status, insurance type, BMI, number of comorbidities). Descriptive, comparative, and correlational statistics are used.Results: N = 173 patients. No significant demographic differences in TTI or TTP. In the multivariate model TTI to death, patients with Medicaid insurance had significantly shorter overall survival than patients with private insurance.Conclusions: Medicaid insurance is associated with worse outcomes of MBC therapy, not attributed to TTI delay. Personalization of support may be helpful.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-4"},"PeriodicalIF":3.0,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0